Table 1. Antimicrobial resistance of ESBL-EC and non-ESBL-EC isolates.
| Antimicrobial agent | ESBL-EC (n = 30) | Non-ESBL-EC (n = 85) | P value |
|---|---|---|---|
| Piperacillin-tazobactam | 5 (16.7) | 1 (1.2) | .005 |
| Cefmetazole | 5 (16.7) | 2 (2.4) | .01 |
| Flomoxef | 1 (3.3) | 1 (1.2) | .46 |
| Imipenem | 1 (3.3) | 0 | .26 |
| Meropenem | 1 (3.3) | 0 | .26 |
| Gentamicin | 12 (40) | 5 (5.9) | < .001 |
| Tobramycin | 12 (40) | 5 (5.9) | < .001 |
| Amikacin | 1 (3.3) | 0 | .26 |
| Levofloxacin | 24 (80) | 14 (16.5) | < .001 |
| Ciprofloxacin | 25 (83.3) | 13 (15.3) | < .001 |
| Fosfomycin* | 0 | 3 (3.5) | .57 |
| Trimethoprim-sulfamethoxazole | 15 (50) | 15 (17.6) | < .001 |
Data are presented as n (%). ESBL-EC, extended-spectrum beta-lactamase-producing E. coli; non-ESBL-EC, non-extended-spectrum beta-lactamase-producing E. coli.
* Clinical Laboratory Standards Institute breakpoint is available for urine isolates only.